Ingrid Mayer
Vanderbilt-Ingram Cancer Center · ECOG-ACRIN Cancer Research Group
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Registry trials as an overall official
15
all conditions, ClinicalTrials.gov
NIH grants tied to them
3
NIH RePORTER
Trial papers in breast cancer
55
PubMed author-name match
Trials
Studies that name Ingrid Mayer as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:29 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT03566485 · Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast CancerVanderbilt-Ingram Cancer Center · terminated · Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer · principal investigator
- Ph3NCT02445391 · Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant ChemotherapyECOG-ACRIN Cancer Research Group · active not recruiting · Estrogen Receptor Negative, HER2/Neu Negative, Invasive Breast Carcinoma · principal investigator
- Ph1NCT01248494 · PhIb BKM120 or BEZ235+Endocrine Treatment in Post-Menopausal Patients With Hormone Receptor + Metastatic Breast CancerVanderbilt-Ingram Cancer Center · completed · Metastatic Breast Cancer · principal investigator
- Ph2NCT01205685 · Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-Sensitive Metastatic Breast CancerVanderbilt-Ingram Cancer Center · terminated · Hormone-sensitive Metastatic Breast Cancer · principal investigator
- N/ANCT01096381 · Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid TumorVanderbilt-Ingram Cancer Center · terminated · Breast Cancer, Cardiovascular Complications, Colorectal Cancer · principal investigator
- Ph1/Ph2NCT01031446 · Cisplatin, Paclitaxel, and Everolimus in Treating Patients With Metastatic Breast CancerVanderbilt-Ingram Cancer Center · completed · Breast Cancer · principal investigator
- Ph2NCT01013506 · Phase 2, Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-sensitive Metastatic Breast CancerVanderbilt-Ingram Cancer Center · withdrawn · Breast Cancer · principal investigator
- N/ANCT00984490 · Metformin Hydrochloride in Treating Women With Stage I or Stage II Breast Cancer That Can Be Removed By SurgeryVanderbilt-Ingram Cancer Center · terminated · Breast Cancer · principal investigator
- Ph2NCT00930930 · Cisplatin and Paclitaxel With or Without Everolimus in Treating Patients With Stage II or Stage III Breast CancerVanderbilt-Ingram Cancer Center · completed · Breast Cancer · principal investigator
- Ph1NCT00680758 · Cisplatin, Paclitaxel, and Everolimus in Treating Patients With Metastatic Breast CancerVanderbilt-Ingram Cancer Center · completed · Breast Cancer · study chair
- Ph2NCT00611715 · Ph II Letrozole + OSI-774 (Tarceva) in Post-menopausal, w/ ER and/or PR-positive Met Breast Cancer.Vanderbilt-Ingram Cancer Center · terminated · Breast Cancer · study chair
- Ph1NCT00574366 · Erlotinib and Everolimus in Treating Patients With Metastatic Breast CancerVanderbilt-Ingram Cancer Center · completed · Breast Cancer · study chair
- Ph3NCT00520975 · Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEUNational Cancer Institute (NCI) · terminated · Breast Carcinoma, Recurrent Breast Carcinoma, Stage IV Breast Cancer · principal investigator
- Ph2NCT00499681 · PhII Neo-Adjuvant Letrozole & Lapatinib in Pts w/HER2+ & Hormone Receptor+ Operable Breast CA SPOREVanderbilt-Ingram Cancer Center · terminated · Breast Cancer · study chair
- Ph2NCT00006104 · Trastuzumab Plus Docetaxel in Treating Women With Recurrent or Metastatic Breast CancerVanderbilt-Ingram Cancer Center · completed · Breast Cancer · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:29 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Breast Cancer Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · fiscal years 2020 to 2021 · $89,432 awarded in 2021Grant number is on one of their registry trials
- SPORE in Breast CancerP50CA098131 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · fiscal years 2008 to 2020 · $2,088,032 awarded in 2020Same name and institution; not confirmed by an ID
- Targeted Therapies in Breast CancerK23CA127469 · NCI · VANDERBILT UNIVERSITY · fiscal years 2009 to 2013 · $163,944 awarded in 2013Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- ECOG-ACRIN Network Group Operations CenterU10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer, MITCHELL D. SCHNALL · fiscal years 2014 to 2026Named on NCT02445391
- ECOG-ACRIN Biospecimen Bank to Support NCTNU24CA196172 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI STANLEY R. HAMILTON, Scott D Jewell · fiscal years 2015 to 2026Named on NCT02445391
- ECOG-ACRIN Network Group Statistics and Data Management CenterU10CA180794 · NCI · DANA-FARBER CANCER INST · PI PAUL J CATALANO, CONSTANTINE A. GATSONIS · fiscal years 2014 to 2026Named on NCT00520975
- ECOG Statistical OfficeU10CA023318 · NCI · DANA-FARBER CANCER INST · PI ROBERT J GRAY · fiscal years 1985 to 2013Named on NCT00520975
Most cited trial papers
Clinical-trial papers with this author name in breast cancer, ranked by citations from NIH iCite, fetched 2026-11-12 10:29 UTC. The ranking covers the 200 most relevant of 55 PubMed records, and a shared surname and initials can bring in a namesake. All 55 on PubMed
- 2,116 citationsRCR 82.3
- Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.N Engl J Med · 20181,861 citationsRCR 66.8
- Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.N Engl J Med · 20151,025 citationsRCR 31.5
- Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer.N Engl J Med · 2019713 citationsRCR 26.7
- 508 citationsRCR 27.0
- Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer.N Engl J Med · 2019424 citationsRCR 14.9
- Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.J Clin Oncol · 2017349 citationsRCR 10.7
- A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer.Clin Cancer Res · 2017263 citationsRCR 7.6
- 252 citationsRCR 7.5
- 238 citationsRCR 6.0